Profile data is unavailable for this security.
About the company
Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
- Revenue in JPY (TTM)756.23bn
- Net income in JPY47.95bn
- LocationEisai Co LtdEisai Main Bldg., 4-6-10, KoishikawaBUNKYO-KU 112-8088JapanJPN
- Phone+81 338173700
- Fax+81 338113305
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|4523:TYO since |
|Sunplanet Co Ltd||Announced||30 May 2022||30 May 2022Announced||4.55%||2.98m|
|Arteryex Inc||Deal completed||31 Mar 2022||31 Mar 2022Deal completed||-4.25%||--|